OPUS GENETICS INC.
Gene therapies for inherited retinal diseases and refractive disorders
- Sector
- Biotech
- Headquarters
- Farmington Hills, MI
- Latest Form D
- $26M, Nov 2024
- Total capital
- $49M
- Grants
- $1.7M
- 2 awards
- 2.0× sector median 1 award
- Raised
- $47M
- 2 Form D · Nov 2024
- 23 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 10 granted · 30 pending
- 20× sector median 2 patents
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · A single mutation-independent AAV gene therapy for the treatment of autosomal-dominant retinitis pigmentosa. | $836,933 | |
| Private capital raised | Form D · SEC | $25,778,641 | |
| Federal grant | Department of Health and Human Services · Phase II · A single mutation-independent AAV gene therapy for the treatment of autosomal-dominant retinitis pigmentosa. | $882,971 | |
| Private capital raised | Form D · SEC | $21,150,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3387 | BlueSphere Bio, Inc. | — | $56M |
| 3388 | Life Biosciences LLC | — | $54M |
| 3389 | PhaseBio Pharmaceuticals Inc | — | $64M |
| 3390 | OPUS GENETICS INC. | — | $47M |
| 3391 | CERo Therapeutics, Inc. | — | $45M |
| 3392 | Forte Biosciences | — | $44M |
| 3393 | Oncotelic Therapeutics, Inc. | — | $40M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Sean AinsworthDirector
- Dr. Jean BennettDirector
- Susan BentonDirector
- Cam GallagherDirector
- Dr. Adrienne GravesDirector
- Bernhard HoffmannExecutive Officer
- Ash JayagopalExecutive Officer
- Nirav JhaveriExecutive Officer
Show all 17 people
- Dr. George MagrathDirector · Executive Officer
- James ManusoDirector
- Alan MeyerDirector
- Amy RabournExecutive Officer
- Richard RodgersDirector
- Joseph SchachleExecutive Officer
- Mina SoochDirector · Executive Officer
- Dr. Benjamin YerxaDirector · Executive Officer
- Amy Zaremba RabournExecutive Officer
Patents
- Highly Pure Phentolamine Mesylate And Methods For Making Samegranted
- Aqueous Ophthalmic Solutions Of Phentolamine And Medical Uses Thereofgranted
- Methods And Compositions For Treatment Of Mydriasisapplication
- Aqueous Ophthalmic Solutions Of Phentolamine And Medical Uses Thereofgranted
- Gene Therapy For Ocular Diseaseapplication
- Methods And Compositions For Preventing The Progression Of Diabetic Retinopathy And Related Conditionsapplication
- Methods And Compositions For Treatment Of Mydriasisgranted
- Methods And Compositions For Treatment Of Mydriasisgranted
- Aqueous Ophthalmic Solutions Of Phentolamine And Medical Uses Thereofapplication
- Aqueous Ophthalmic Solutions Of Phentolamine And Medical Uses Thereofapplication
- Aqueous Ophthalmic Solutions Of Phentolamine And Medical Uses Thereofapplication
- Aqueous Ophthalmic Solutions Of Phentolamine And Medical Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.